USFDA issues Form-483 with two observations for Lupin's Nagp

Lupin's Nagpur facility has received two observations from the USFDA through Form-483 due to violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The company assured that it would resolve the issues raised and is confident of doing so soon. The USFDA conducted an inspection of the facility from July 3-11, 2023.

Related Keywords

Nagpur , Maharashtra , India , Mumbai , Nilesh Gupta , Drug Administration , Food Drug , Establishment Inspection Report , Voluntary Action Indicated , Managing Director Nilesh Gupta ,